Ozempic and Wegovy also useful for Afib?

Did you know that the same medications millions of people take for weight loss and type 2 diabetes might also be protecting them from atrial fibrillation?

Semaglutide, the active ingredient behind Ozempic and Wegovy, was never designed with heart rhythm in mind. But a growing body of research suggests the drugs are beneficial for your heart health , and researchers, including our own AFIP team, are paying close attention.

Here’s what we know so far:

GLP-1 receptor agonists: your body’s natural appetite regulator

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after eating. It nudges your pancreas to release insulin, slows down how quickly your stomach empties, and dampens appetite. Semaglutide is a lab-made version of this hormone, engineered to stay active in the body far longer, which is exactly what makes it so effective for blood sugar control and weight loss.

In large clinical trials, people taking weekly semaglutide lost an average of around 15% of their body weight over 68 weeks. Tirzepatide, a newer drug that works in a similar way, pushed that figure up to around 20%.

The benefits do not stop at the scale. Major cardiovascular trials have linked these medications to a lower risk of heart attack, stroke, and cardiovascular death, benefits that go beyond what weight loss alone would explain.

Have you noticed a change in your heart health since starting a GLP-1 medication? It’s exactly this kind of real-world experience that helps researchers understand what these drugs are really doing.

Waarom kunnen deze medicijnen specifiek helpen bij boezemfibrilleren?

There are a few plausible explanations, and they are not mutually exclusive.

Weight loss

Obesity is one of the most well established lifestyle risk factors for Afib. Extra weight changes both the structure and the electrical behaviour of the atria, the heart’s upper chambers, in ways that make Afib more likely and harder to treat. The LEGACY study found that losing at least 10% of body weight led to a clear drop in Afib episodes and symptom severity, with the biggest benefit going to those who lost the most and kept it off.

Less inflammation

Inflammation is believed to help drive the tissue changes that allow Afib to take hold. The SELECT trial, which followed over 17,000 people with obesity and cardiovascular disease but no diabetes, found that semaglutide produced a lasting drop in a blood marker of inflammation called hsCRP, and the improvement was larger than weight loss alone could explain.

A possible direct effect on the heart

GLP-1 receptors, the targets these drugs bind to, sit not only in the gut and brain but also in heart tissue, including the atria. Early laboratory and animal research suggests activating these receptors may reduce fibrosis, the scarring that helps sustain Afib, and may influence the autonomic nervous system that governs heart rhythm.

This part of the story is still early-stage, so it is worth treating with appropriate caution.

GLP-1s have been linked to better treatment outcomes for Afib

Semaglutide after ablation. One study looked at whether semaglutide could improve outcomes after catheter ablation in people with Afib and obesity. Researchers compared 181 people who started semaglutide around the time of their ablation with 181 similar people who did not take a GLP-1 drug, tracking everyone’s heart rhythm continuously for up to 18 months.

The result: 80% of the semaglutide group stayed free of Afib recurrence, compared with 65% in the comparison group. The semaglutide group also lost significantly more weight. It is a single-centre study, so larger trials are needed before drawing firm conclusions, but the signal is a promising one.

SELECT and cardiovascular outcomes. The SELECT trial randomly assigned over 17,000 people with obesity and existing cardiovascular disease to either semaglutide or a placebo.

After roughly three years, the semaglutide group had a 20% lower risk of serious cardiovascular events, alongside a sustained drop in inflammatory markers. Afib itself was not the focus of this trial, but the findings are directly relevant to the question researchers are now asking.

Liraglutide and LEADER. The LEADER trial enrolled over 9,000 people with type 2 diabetes at high cardiovascular risk and compared liraglutide with a placebo. Over almost four years, liraglutide cut major cardiovascular events by 13%. It was one of the first large trials to hint that GLP-1 drugs offer benefits beyond blood sugar, and it helped set the stage for the research being done today.

Watch out for dehydration and electrolyte imbalances

GLP-1 medicines slow digestion, which is part of why they work so well, but it also explains why nausea, vomiting, and diarrhoea are common early on. A 2022 multidisciplinary consensus review found these digestive symptoms affect roughly 40 to 70 percent of people starting treatment, usually mild and settling within a few weeks, a finding echoed by a larger 2025 analysis of over 33,000 people.

If vomiting or diarrhoea become frequent, the body can lose potassium and magnesium, two minerals your heart relies on to keep a steady beat. Low levels of either are known to trigger irregular heart rhythms, including Afib. The reassuring part: the largest studies to date, covering nearly 80,000 people, found that GLP-1 medicines do not raise Afib risk overall.

One simple, practical safeguard from the consensus guidance: staying generously hydrated during bouts of vomiting or diarrhoea is one of the easiest ways to protect against this. If symptoms last more than a day or two, it is worth checking in with your doctor, since catching a mineral dip early is a simple fix.

The guidelines support managing obesity: could GLP-1 drugs be the future?

Neither the 2024 ESC Guidelines nor the 2023 ACC/AHA Guidelines currently recommend GLP-1 drugs specifically for Afib treatment. Trials with Afib recurrence as their primary endpoint are still underway. Both guidelines do, however, give their strongest recommendation to weight management for people with Afib who are overweight or have obesity, and GLP-1 drugs are already an established, effective tool for that.

For people managing Afib alongside obesity or type 2 diabetes, these medications may be addressing several priorities at once. As the evidence builds, it is likely that future guideline updates will speak to GLP-1 drugs and Afib more directly.

What this means for you

Large trials like SELECT and LEADER tell us what happens on average across thousands of people, but they cannot tell you how a medication will work for you specifically.

Have you started a GLP-1 medication and noticed a change, for better or worse, in how often your Afib shows up?

That kind of lived experience is exactly what helps researchers, including the AFIP team, understand which patients benefit most and why.

If you are living with both Afib and obesity or type 2 diabetes, it may be worth raising GLP-1 medications with your healthcare team as part of a broader conversation about your treatment. And if you have your own experience to share, we would love to hear it, your story could be exactly the kind of real-world signal that shapes where our research goes next.

As always, speak with your healthcare provider before making any changes to your treatment or routine.